Invivyd Inc.
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which i… Read more
Invivyd Inc. (IVVD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.064x
Based on the latest financial reports, Invivyd Inc. (IVVD) has a cash flow conversion efficiency ratio of -0.064x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.46 Million) by net assets ($241.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Invivyd Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Invivyd Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Invivyd Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OKUMF
OTCGREY:OKUMF
|
N/A |
|
YC Inox Co Ltd
TW:2034
|
0.044x |
|
Hankook Shell Oil
KO:002960
|
0.127x |
|
KraussMaffei Co Ltd
SHG:600579
|
0.016x |
|
CHEMTRONICS.CO.Ltd
KQ:089010
|
0.121x |
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507
|
N/A |
|
Reysas Gayrimenkul Yatirim Ortakligi A.S.
PINK:RYGYF
|
0.013x |
|
Cera Sanitaryware Limited
NSE:CERA
|
0.055x |
Annual Cash Flow Conversion Efficiency for Invivyd Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Invivyd Inc. from 2020 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $241.54 Million | $-58.13 Million | -0.241x | +90.47% |
| 2024-12-31 | $67.54 Million | $-170.49 Million | -2.524x | -158.71% |
| 2023-12-31 | $177.47 Million | $-173.16 Million | -0.976x | -57.89% |
| 2022-12-31 | $355.97 Million | $-219.99 Million | -0.618x | -86.67% |
| 2021-12-31 | $558.02 Million | $-184.74 Million | -0.331x | -248.25% |
| 2020-12-31 | $-65.25 Million | $-14.57 Million | 0.223x | -- |